SV-BR-1-GM + cyclophosphamide + interferon alpha-2b

This is a combination immunotherapy regimen for advanced or metastatic breast cancer, consisting of three components: 1. **SV-BR-1-GM**: An allogeneic, whole-cell breast cancer vaccine derived from the SV-BR-1 cell line, genetically engineered to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF). The vaccine presents tumor-associated antigens and functions as an antigen-presenting cell, stimulating both CD4+ and CD8+ T cells to induce a tumor-directed immune response. It is designed to enhance the patient’s immune recognition and destruction of tumor cells[2][3][7]. 2. **Cyclophosphamide**: A small molecule alkylating agent used at low doses prior to vaccination. It acts as an immunomodulator by depleting regulatory T cells (Tregs), thereby enhancing the efficacy of immunotherapies[4][5][7]. 3. **Interferon alpha‑2b**: A recombinant cytokine administered locally at the inoculation sites after vaccination. It further stimulates local immune activation and enhances antigen presentation[4][5][7]. The regimen has been evaluated in phase I/II clinical trials for patients with advanced or refractory metastatic breast cancer, showing disease control in some patients—particularly those with HLA matches to the vaccine—and was generally well tolerated[5]. The combination aims to maximize anti-tumor immunity through synergistic effects on both innate and adaptive immune responses.

Brand names

Bria-IMT

Other names

allogeneic GM-CSF-secreting breast cancer vaccineGM-CSF gene-transfected breast cancer vaccineSV-BR1-GM-breast-cancer-vaccineSV-BR-1-GM-breast-cancer-vaccineSV-BR 1-GM-breast-cancer-vaccine